---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-002488"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-01-28T23:59:59+00:00"
generated_at: "2026-06-27T14:32:40.115249+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oncotelic updates on OT-101 biomarker program pursuing accelerated approval route for solid tumors

## Summary
- New corporate presentation highlights OT-101 biomarker program with pembrolizumab in multiple phase 2 trials.
- Aims to leverage FDA accelerated approval pathway for TMB-H solid tumors, similar to pembrolizumab's June 2020 approval.
- Phase 2 trials target solid tumors with high-TGF signature, using a companion diagnostic assay.

## SEC filing metadata
- accession: 0001493152-22-002488
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222002488/0001493152-22-002488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222002488/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-002488
- JSON: https://secwatch.observer/filing/0001493152-22-002488.json
- Plain text: https://secwatch.observer/filing/0001493152-22-002488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.